Day: March 1, 2025

Notification of transaction by an Officer of Millicom (Tigo)  Luxembourg, March 1, 2025 – Millicom International Cellular S.A. (“Millicom” or the “Company”) announces that, on February 27, 2025, under an existing 10b5-1 plan, Mr. Salvador Escalon, Chief Legal and Compliance Officer, sold 10,991 Millicom shares in the open market at an average price of $28.8473 per share. As a result, Salvador Escalon currently owns 151,410 shares. Details of the transaction are recorded on the personal trading section of Millicom’s website.  For further information, please contact:Press: Sofía Corral, Director Corporate Communications press@millicom.com Investors: Michel Morin, VP Investor Relations investors@millicom.com About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of...

REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting updated clinical data from the Phase 1b/2a BEACON study, as well as data from four preclinical studies evaluating briquilimab, at the AAAAI 2025 Annual Meeting, being held February 28 – March 3, 2025, in San Diego, CA. The BEACON update, based on a data-cut date of January 31, 2025, features approximately one month of additional dosing and follow-up from the 49 participants covered in Jasper’s preliminary data disclosure on January 8, 2025. Briquilimab continues...

– Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU –– 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 –– 60% of CIndU patients reported that symptoms no longer had an impact on their quality of life at Week 12 – HAMPTON, N.J., March 01, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive data on measurements of disease control and quality of life from the Company’s Phase 2 barzolvolimab studies in patients with chronic urticaria. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. In a Phase...

13,192 vehicles were delivered in February 2025, increasing by 62.2% year-over-year 27,055 vehicles were delivered year-to-date in 2025, increasing by 48.8% year-over-year Cumulative deliveries reached 698,619 as of February 28, 2025  SHANGHAI, China, March 01, 2025 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its February 2025 delivery results. The Company delivered 13,192 vehicles in February 2025, representing an increase of 62.2% year-over-year. The deliveries consisted of 9,143 vehicles from the Company’s premium smart electric vehicle brand NIO, and 4,049 vehicles from the Company’s family-oriented smart electric vehicle brand ONVO. Cumulative deliveries reached 698,619 as of February...

Delivers 30,453 units in February, up 570% YoY XPENG MONA M03 deliveries surpass 15,000 units for three consecutive months XPENG P7+ surpassed 30,000 cumulative deliveries within just three months of its launchGUANGZHOU, China, March 01, 2025 (GLOBE NEWSWIRE) — XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced its vehicle delivery results for February 2025. XPENG delivered 30,453 Smart EVs in February, marking a 570% increase year-over-year. Deliveries of the XPENG MONA M03 surpassed 15,000 units for the third consecutive month, while cumulative deliveries of the XPENG P7+ exceeded 30,000 within the first three months of its launch. Moreover, XPENG uncovered the user profile of XPENG P7+, pointing to smart driving being one of the...

BEIJING, China, Feb. 28, 2025 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 26,263 vehicles in February 2025, representing a year-over-year increase of 29.7%. As of February 28, 2025, Li Auto’s cumulative deliveries reached 1,190,062. In February, the Company rolled out OTA update version 7.1 to all users, further enhancing the capabilities of its autonomous driving and smart space systems. The newly upgraded Li AD Max V13 now delivers smoother performance when navigating complex road conditions, while new features, such as Sentry Mode High-Risk Video Remote Preview and Front Passenger Exit Alert, provide a more reassuring user experience. Additionally, Li Auto unveiled the exterior design of its first battery...